Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00289939 · ClinicalTrials.gov registry record · Phase 3

Reducing HIV & Domestic Violence Risk in Women Offenders

A Phase 3 study of HIV Infections and Sexually Transmitted Diseases, sponsored by Multnomah County Health Department.

Completed
Registry status
Phase 3
Development phase
530
Enrollment target
1
Study location

NCT00289939: Completed Phase 3 study of HIV Infections and Sexually Transmitted Diseases, sponsored by Multnomah County Health Department.

NCT00289939 is a Phase 3 study of HIV Infections and Sexually Transmitted Diseases that has completed, run by Multnomah County Health Department. The registered enrollment target is 530 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00289939, a Phase 3 study of HIV Infections and Sexually Transmitted Diseases, has completed, sponsored by Multnomah County Health Department.

COMPLETED
Registry status
Phase 3
Development phase
530 participants
Enrollment target
1
Study location

Study Summary

The long-term goal of this work is to reduce the prevalence of HIV and domestic violence among women at risk by encouraging self-protective behaviors. To obtain this goal, Multnomah County Health Department and Oregon Department of Human Services have conducted a randomized trial of an intervention to prevent HIV and domestic violence among women who have recent criminal justice involvement and who are at risk for HIV infection. Women enrolled in the study were randomly assigned to one of three study conditions: * Group 1: these women received information on local resources addressing HIV prevention, domestic violence, and life stability issues; they did not receive any counseling sessions as part of the study itself. * Group 2: these women received up to ten supportive counseling sessions based on the techniques of motivational interviewing. These sessions aimed to reduce HIV risk and to improve life stability. * Group 3: these women received up to ten supportive counseling sessions based on motivational interviewing. These sessions aimed to reduce risk for HIV and domestic violence and to improve life stability. The primary hypotheses of this study were: * 1\. Supportive counseling (motivational interviewing) addressing HIV prevention and increased life stability will lead to reductions of HIV risk behavior among women enrolled in the study. * 2\. Supportive counseling (motivational interviewing) addressing domestic violence prevention, HIV prevention, and increased life stability, will bring about reductions in experiences of domestic violence and a reduction of HIV risk among these women. * 3\. The supportive counseling received in this study will enhance these women's self-efficacy, self-esteem, and psychological well-being. Women in all three experimental groups were interviewed at the beginning of the study and again after 4, 7, and 10 months. These assessment interviews asked questions about: HIV risk; experiences of domestic violence; and life stabilit

Interventions

  • BEHAVIORAL Motivational interviewing to reduce risk for HIV and DV

Study Locations (1)

Oregon

  • SE Health Center - Portland

Trial Details

FieldValue
Enrollment Target 530 participants
Start Date 2000-09
Est. Completion 2005-01
Phase Phase 3

What the finished NCT00289939 record still lists

NCT00289939 is an interventional study that assigns participants to a tested intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (19% higher).

The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Motivational interviewing to reduce risk for HIV and DV is the first listed.

NCT00289939 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT00289939 about?

NCT00289939 is a clinical study titled "Reducing HIV & Domestic Violence Risk in Women Offenders". The long-term goal of this work is to reduce the prevalence of HIV and domestic violence among women at risk by encouraging self-protective behaviors. To obtain this goal, Multnomah County Health Department and Oregon Department of Human Services have conducted a randomized trial of an intervention ...

What is the current status of trial NCT00289939?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2000-09. Estimated completion is 2005-01.

What conditions does trial NCT00289939 study?

This clinical trial studies the following conditions: HIV Infections, Sexually Transmitted Diseases, Domestic Violence.

What interventions are being tested in trial NCT00289939?

The interventions under investigation include: Motivational interviewing to reduce risk for HIV and DV (BEHAVIORAL).

Who is sponsoring clinical trial NCT00289939?

This trial is sponsored by Multnomah County Health Department, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00289939 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00289939's enrollment target sits among peer trials

530 58th of 542 higher than 485 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06646276 · 530 participants · Phase 3

    A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  • NCT06703476 · 530 participants · Phase 3

    A Study of Surgical Techniques During Cystectomy

  • NCT06880744 · 530 participants · Phase 3

    A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  • NCT07138040 · 530 participants · NA

    Re-Engaging AYA Survivors in Cancer-Related Healthcare

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00289939, the US trial registry maintained by the National Library of Medicine. NCT00289939 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.